[1] TANG A, HALLOUCH O, CHERNYAK V, et al. Epidemiology of hepatocellular carcinoma:target population for surveillance and diagnosis[J]. Abdom Radiol(NY), 2018, 43(1):13-25.
[2] BRUIX J, REIG M, SHERMAN M.Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma[J]. Gastroenterology, 2016, 150(4):835-853.
[3] CHOTI M A, THOMAS M, WONG S L, et al. Surgical resection preferences and perceptions among medical oncologists treating liver metastases from colorectal cancer[J]. Ann Surg Oncol, 2016, 23(2):375-381.
[4] KANWAL F, SINGAL A G.Surveillance for hepatocellular carcinoma:current best practice and future direction[J]. Gastroenterology, 2019, 157(1):54-64.
[5] FUJIWARA N, FRIEDMAN S L, GOOSSENS N, et al. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine[J]. J Hepatol, 2018, 68(3):526-549.
[6] WAKABAYASHI G, CHERQUI D, GELLER D A, et al. Recommendations for laparoscopic liver resection:a report from the second international consensus conference held in Morioka[J]. Ann Surg, 2015, 261(4):619-629.
[7] CIRIA R, CHERQUI D, GELLER D A, et al. Comparative short-term benefits of laparoscopic liver resection:9000 cases and climbing[J]. Ann Surg, 2016, 263(4):761-777.
[8] KIM J H.Three-dimensional ventral approach with the modified liver-Hanging maneuver during laparoscopic right hemihepatectomy[J]. Ann Surg Oncol, 2019, 26(7):2253.
[9] VELAYUTHAM V, FUKS D, NOMI T, et al. 3D visualization reduces operating time when compared to high-definition 2D in laparoscopic liver resection:a case-matched study[J]. Surg Endosc, 2016, 30(1):147-153.
[10] HONG S K, SUH K S, KIM H S, et al. Pure 3D laparoscopic living donor right hemihepatectomy in a donor with separate right posterior and right anterior hepatic ducts and portal veins[J]. Surg Endosc, 2017, 31(11):4834-4835.
[11] LUO H, YIN D, ZHANG S, et al. Augmented reality navigation for liver resection with a stereoscopic laparoscope[J]. Comput Methods Programs Biomed, 2020, 187:105099.
[12] PETERS B S, ARMIJO P R, KRAUSE C, et al. Review of emerging surgical robotic technology[J]. Surg Endosc, 2018, 32(4):1636-1655.
[13] LI C G, ZHOU Z P, TAN X L, et al. Robotic resection of liver focal nodal hyperplasia guided by indocyanine green fluorescence imaging:a preliminary analysis of 23 cases[J]. World J Gastrointest Oncol, 2020, 12(12):1407-1415.
[14] RUDNICK S R, RUSSO M W.Liver transplantation beyond or downstaging within the milan criteria for hepatocellular carcinoma[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(3):265-275.
[15] KARDASHIAN A, FLORMAN S S, HAYDEL B, et al. Liver transplantation outcomes in a U.S.multicenter cohort of 789 patients with hepatocellular carcinoma presenting beyond milan criteria[J]. Hepatology, 2020, 72(6):2014-2028.
[16] BODZIN A S, BAKER T B.Liver transplantation today:where we are now and where we are going[J]. Liver Transpl, 2018, 24(10):1470-1475.
[17] MILLER C M, QUNINTINI C, DHAWAN A, et al. The international liver transplantation society living donor liver transplant recipient guideline[J]. Transplantation, 2017, 101(5):938-944.
[18] RAOUL J L, FORNER A, BOLONDI L, et al. Updated use of TACE for hepatocellular carcinoma treatment:How and when to use it based on clinical evidence[J]. Cancer Treat Rev, 2019, 72:28-36.
[19] YOON S M, RYOO B Y, LEE S J, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion:a randomized clinical trial[J]. JAMA Oncol, 2018, 4(5):661-669.
[20] GALLE P R, TOVOLI F, FOERSTER F, et al. The treatment of intermediate stage tumours beyond TACE:From surgery to systemic therapy[J]. J Hepatol, 2017, 67(1):173-183.
[21] MONIER A, GUIU B, DURAN R, et al. Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma:comparison between drug-eluting beads and lipiodol emulsion[J]. Eur Radiol, 2017, 27(4):1431-1439.
[22] KUDO M, UESHIMA K, IKEDA M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation(TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma:TACTICS trial[J]. Gut, 2020, 69(8):1492-1501.
[23] HINDSON J.Combined TACE and sorafenib for HCC treatment[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(2):66.
[24] IZZO F, GRANATA V, GRASSI R, et al. Radiofrequency ablation and microwave ablation in liver tumors:an update[J]. Oncologist, 2019, 24(10):e990-e1005.
[25] XU X L, LIU X D, LIANG M, et al. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma:systematic review of randomized controlled trials with meta-analysis and trial sequential analysis[J]. Radiology, 2018, 287(2):461-472.
[26] TAN W, DENG Q, LIN S, et al. Comparison of microwave ablation and radiofrequency ablation for hepatocellular carcinoma:a systematic review and meta-analysis[J]. Int J Hyperthermia, 2019, 36(1):264-272.
[27] RAJYAGURU D J, BORGERT A J, SMITH A L, et al. Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients:analysis of the national cancer database[J]. J Clin Oncol, 2018, 36(6):600-608.
[28] ZAHEER J, KIM H, LEE Y J, et al. Combination radioimmunotherapy strategies for solid tumors[J]. Int J Mol Sci, 2019, 20(22):5579.
[29] RODRIGUEZ-RUIZ M E, RODRIGUEZ I, LEAMAN O, et al. Immune mechanisms mediating abscopal effects in radioimmunotherapy[J]. Pharmacol Ther, 2019, 196:195-203.
[30] SHENG H, HUANG Y, XIAO Y, et al. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma[J]. J Immunother Cancer, 2020, 8(1):e000340.
[31] KLINGLER S, FAY R, HOLLAND J P.Light-induced radiosynthesis of (89)Zr-DFO-Azepin-Onartuzumab for imaging the hepatocyte growth factor receptor[J]. J Nucl Med, 2020, 61(7):1072-1078.
[32] SUBBIAH V, ERWIN W, MAWLAWI O, et al. Phase I Study of p-cadherin-targeted radioimmunotherapy with (90)Y-FF-21101 monoclonal antibody in solid tumors[J]. Clin Cancer Res, 2020, 26(22):5830-5842.
[33] KODAIRA S, MOROKOSHI Y, LI H K, et al. Evidence of local concentration of α-Particles from (211)At-labeled antibodies in liver metastasis tissue[J]. J Nucl Med, 2019, 60(4):497-501.
[34] TU J, JI J, WU F, et al. Effectiveness of combined (131)I-chTNT and radiofrequency ablation therapy in treating advanced hepatocellular carcinoma[J]. Cell Biochem Biophys, 2015, 71(2):777-784.
[35] WANG C, JIN H, GAO D, et al. Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer[J]. J Hepatol, 2018, 69(5):1057-1065.
[36] LLOVET J M, MONTAL R, SIA D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma[J]. Nat Rev Clin Oncol, 2018, 15(10):599-616.
[37] LIU Z, LIN Y, ZHANG J, et al. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2019, 38(1):447.
[38] SONG Z, LIU T, CHEN J, et al. HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib[J]. Cancer Lett, 2019, 460:96-107.
[39] VIVEIROS P, RIAZ A, LEWANDOWSKI R J, et al. Current state of liver-directed therapies and combinatory approaches with systemic therapy in hepatocellular carcinoma(HCC)[J]. Cancers(Basel), 2019, 11(8):1085.
[40] ZHU K, HUANG J, LAI L, et al. Medium or large hepatocellular carcinoma:sorafenib combined with transarterial chemoembolization and radiofrequency ablation[J]. Radiology, 2018, 288(1):300-307.
[41] ZHAO Y, ZHANG Y N, WANG K T, et al. Lenvatinib for hepatocellular carcinoma:From preclinical mechanisms to anti-cancer therapy[J]. Biochim Biophys Acta Rev Cancer, 2020, 1874(1):188391.
[42] MATSUKI M, HOSHI T, YAMAMOTO Y, et al. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models[J]. Cancer Med, 2018, 7(6):2641-2653.
[43] GORDAN J D, KENNEDY E B, ABOU-ALFA G K, et al. Systemic therapy for advanced hepatocellular carcinoma:ASCO guideline[J]. J Clin Oncol, 2020, 38(36):4317-4345.
[44] SPALLANZANI A, ORSI G, ANDRIKOU K, et al. Lenvatinib as a therapy for unresectable hepatocellular carcinoma[J]. Expert Rev Anticancer Ther, 2018, 18(11):1069-1076.
[45] NISHIJIMA T F, SHACHAR S S, NYROP K A, et al. Safety and tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer:a Meta-analysis[J]. Oncologist, 2017, 22(4):470-479.
[46] ZHOU Y, LI Y, ZHOU T, et al. Dietary natural products for prevention and treatment of liver cancer[J]. Nutrients, 2016, 8(3):156.
[47] LIU C, YANG S, WANG K, et al. Alkaloids from traditional Chinese medicine against hepatocellular carcinoma[J]. Biomed Pharmacother, 2019, 120:109543.
[48] LIU X, LI M, WANG X, et al. Effects of adjuvant traditional Chinese medicine therapy on long-term survival in patients with hepatocellular carcinoma[J]. Phytomedicine, 2019, 62:152930.
[49] YANG Y, SUN M, YAO W, et al. Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib[J]. J Immunother Cancer, 2020, 8(1):e000317.
[50] NISHIO T, TAXHIBANA H, KASE Y, et al. Liver phantom design and dosimetric verification in participating institutions for a proton beam therapy in patients with resectable hepatocellular carcinoma:Japan clinical oncology group trial (JCOG1315C)[J]. Radiother Oncol, 2019, 140:98-104.
[51] HONG T S, WO J Y, YEAP B Y, et al. Multi-institutional phase Ⅱ study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. J Clin Oncol, 2016, 34(5):460-468. |
